Clinical Report: How Regulatory Policy Shifts Affect Pharmacy Access to Mifepristone in Australia

Overview

Australia removed prescribing and dispensing restrictions on mifepristone-misoprostol on August 1, 2023, allowing a broader range of qualified practitioners to prescribe and any pharmacist to dispense it. The study described in the source examines whether this change was followed by more pharmacies ordering the medication and a wider geographic distribution; the supplied material does not include its results.

Background

Mifepristone combined with misoprostol is a medication abortion option used in many countries, and medication abortion accounts for nearly half of abortions in Australia. Before August 2023, Australian access was subject to requirements including prescriber training and registration, pharmacist registration, and patient follow-up. The policy change followed consideration of evidence on safety and effectiveness and international experience, and aligned Australia’s dispensing framework more closely with Canada’s. The study was designed to assess pharmacy ordering and geographic distribution after deregulation.

Data Highlights

Key Findings

• The TGA approved mifepristone-misoprostol in Australia in 2012; during the study period, MS Health Pty Ltd was the sole sponsor and distributor of MS-2 Step.
• Before deregulation, Australian requirements included mandatory prescriber training, registration of physicians and pharmacists with the sponsor, registration renewal every 3 years, and compulsory patient follow-up.
• From August 1, 2023, prescribing and dispensing restrictions were removed, and eligible prescribers included appropriately qualified and trained nurse practitioners and endorsed midwives; any pharmacist could dispense.
• The study’s stated outcomes were whether more pharmacies ordered mifepristone-misoprostol and whether the geographic distribution of ordering pharmacies increased after the policy change.
• The supplied article context describes Canada’s 2017 removal of prescribing and dispensing restrictions and reports that safety and effectiveness remained comparable to restricted-distribution settings, while access improved and urban-rural disparities declined.
• The supplied material does not report the Australian study’s findings, so it does not establish whether pharmacy ordering or geographic distribution changed after deregulation.

Clinical Implications

The revised Australian framework permits dispensing through any pharmacist and prescribing by a broader group of appropriately qualified and trained practitioners, as described in the source. The study was intended to evaluate pharmacy ordering and geographic distribution, but its results are not included in the supplied material and therefore cannot support conclusions about observed access changes.

Conclusion

Australia’s August 2023 policy change removed restrictions on prescribing and dispensing mifepristone-misoprostol and broadened eligible prescribers. The supplied source describes the study question and regulatory context but does not provide the study’s results.

Related Resources & Content

1. Therapeutic Goods Administration, TGA, 2023 — Amendments to restrictions for prescribing of MS-2 Step (Mifepristone and Misoprostol)
2. JAMA Network Open, year not stated in supplied material — Regulatory Policy Changes and Mifepristone Access Through Pharmacies in Australia
3. Royal Australian and New Zealand College of Obstetricians and Gynaecologists, 2026 — Clinical Guideline for Abortion Care
4. Stat News — Mifepristone court ruling makes drug development riskier for everyone
5. Stat News — Former FDA leaders, pharma speak out on mifepristone
6. the medicine maker — A Contentious Issue
7. Journal of Medical Internet Research (JMIR) — Perceived Importance of Abortion Care Features and Access to Telehealth Technologies Among Medication Abortion Patients by Abortion Care Model: Cross-Sectional Analysis of a Prospective Cohort Study
8. Amendments to restrictions for prescribing of MS-2 Step (Mifepristone and Misoprostol)
9. Regulatory Policy Changes and Mifepristone Access Through Pharmacies in Australia
10. Clinical Guideline for Abortion Care
11. MS-2 Step | Australian Commission on Safety and Quality in Health Care